Symptomtext
No adverse effect; administered an expired dose of VAQTA; The involved VAQTA had also underwent a temperature excursion.; This spontaneous report was received from a nurse referring to a patient of unknown age and gender. Information regarding the patient's pertinent medical history, drug allergies/reactions, or concomitant medications was not provided. On 20-JAN-2023, the patient was vaccinated with an improperly stored and expired dose of hepatitis a vaccine, inactivated (VAQTA SYRINGE (DEVICE)) for prophylaxis (lot number W007375 had been verified to be a valid number; expiration date 16-JAN-2023, and upon internal validation established as the same date) (dosage, vaccination scheme, frequency, route of administration, and anatomical site of injection were not reported) (expired product administered and product storage error). The administered dose of the vaccine was stored at a temperature of 11.1 degree Celsius (C), for a time frame of 14 hours, as recorded by a data logger. There was no previous temperature excursion reported. There was no adverse effect reported. Follow-up information was received from the nurse on 14-FEB-2023. The report concerns to a 13-month-old female patient, who birth weight was 3.09 kilograms On 20-JAN-2023, the patient was also vaccinated with varicella virus vaccine live (oka/merck) (VARIVAX) subcutaneous injection, lot number U033046 was verified to be a valid number, expiration date 21-OCT-2023, administered subcutaneosly; mumps, and rubella (wistar ra 27-3) virus vaccine, live rHA (recombinant human albumin) (M-M-R II) subcutaneous injection, lot number U039664 was verified to be a valid number, expiration date 15-DEC-2023, administered subcutaneosly; influenza vaccine lot number 5M2H2, expiration date 30-JUN-2023, administered intramuscularly; and pneumococcal vaccine conj 13v (crm197) (PREVENAR 13) lot number FX0079, expiration date 30-NOV-2024, administered intramuscularly, all administered for prophylaxis (doses, strengths, anatomical injection sites and vaccination schemes were not reported). Hepatitis a vaccine, inactivated (VAQTA) was administered intramuscularly. It was reported that temperature excursion was on 12-JAN-2023, vaccines were used on 13-JAN-2023 (also reported as 20-JAN-2023, conflicting information). The vaccines were administered at private doctor's office/hospital with private funds. The reporter considered expired product administered related to hepatitis a vaccine, inactivated (VAQTA).